Yeah, hedge funds like to target promising low float biotech because they're volatile. If a biotech sucks and nobody's buying and its PPS is organically in the doldrums, it isn't as lucrative to short down and it'll just get shorted into the ground quickly, thus ending the game quickly. With Anavex, there is always buying, so the game can be repeated over n over for months-years